Udager Aaron M, Rolland Delphine C M, McHugh Jonathan B, Betz Bryan L, Murga-Zamalloa Carlos, Carey Thomas E, Marentette Lawrence J, Hermsen Mario A, DuRoss Kathleen E, Lim Megan S, Elenitoba-Johnson Kojo S J, Brown Noah A
Department of Pathology, University of Michigan Health System, Ann Arbor, MI.
Department of Otolaryngology/Head and Neck Surgery, University of Michigan Health System, Ann Arbor, MI.
Cancer Res. 2015 Jul 1;75(13):2600-2606. doi: 10.1158/0008-5472.CAN-15-0340. Epub 2015 Apr 30.
Inverted sinonasal papilloma (ISP) is a locally aggressive neoplasm associated with sinonasal squamous cell carcinoma (SNSCC) in 10% to 25% of cases. To date, no recurrent mutations have been identified in ISP or SNSCC. Using targeted next-generation sequencing and Sanger sequencing, we identified activating EGFR mutations in 88% of ISP and 77% of ISP-associated SNSCC. Identical EGFR genotypes were found in matched pairs of ISP and associated SNSCC, providing the first genetic evidence of a biologic link between these tumors. EGFR mutations were not identified in exophytic or oncocytic papillomas or non-ISP-associated SNSCC, suggesting that the ISP/SNSCC spectrum is biologically distinct among sinonasal squamous tumors. Patients with ISP harboring EGFR mutations also exhibited an increased progression-free survival compared with those with wild-type EGFR. Finally, treatment of ISP-associated carcinoma cells with irreversible EGFR inhibitors resulted in inactivation of EGFR signaling and growth inhibition. These findings implicate a prominent role for activating EGFR mutations in the pathogenesis of ISP and associated SNSCC and rationalize consideration of irreversible EGFR inhibitors in the therapy of these tumors.
内翻性鼻窦乳头状瘤(ISP)是一种具有局部侵袭性的肿瘤,在10%至25%的病例中与鼻窦鳞状细胞癌(SNSCC)相关。迄今为止,尚未在ISP或SNSCC中发现复发性突变。通过靶向二代测序和桑格测序,我们在88%的ISP和77%的与ISP相关的SNSCC中发现了激活型表皮生长因子受体(EGFR)突变。在配对的ISP和相关SNSCC中发现了相同的EGFR基因型,为这些肿瘤之间的生物学联系提供了首个遗传学证据。在外生性或嗜酸性细胞瘤或与ISP无关的SNSCC中未发现EGFR突变,这表明在鼻窦鳞状肿瘤中,ISP/SNSCC谱系在生物学上是不同的。与野生型EGFR患者相比,携带EGFR突变的ISP患者的无进展生存期也有所延长。最后,用不可逆EGFR抑制剂治疗与ISP相关的癌细胞导致EGFR信号失活和生长抑制。这些发现表明激活型EGFR突变在ISP和相关SNSCC的发病机制中起重要作用,并为在这些肿瘤的治疗中考虑使用不可逆EGFR抑制剂提供了理论依据。